Twenty-five serum specimens from personnel immunized with botulinum pentavalent toxoid (ABCDE) had titers of neutralizing antibodies to type A (5.7 to 51.6 lU/ml), type B (0.75 to 18 lU/ml), and type E (0.61 to 10 IU/ml) botulinum toxins. Titers for one type could not be used to predict titers for another type in individuals receiving the toxoid. Cross-neutralizing antibodies to type F botulinum toxin were not detected (<0.0125 lU/ml). (2. 3, 12, 15). This is of particular interest because type F botulinum neurotoxin causes human disease. both foodborne (11, 12) and infant (10) botulism. FUrthermore. there are single strains of C. botuidlinwni that produce type F along with another type of neurotoxin: A + F (7), including a strain isolated from a patient with food-borne botulism (5). and B + F. isolated from a case of infant botulism (9). We therefore investigated the possibility that sera from individuals receiving the pentavalent toxoid and having high titers of neutralizing antibodies to type E neurotoxin could also neutralize type F neurotoxin.
Twenty-five serum specimens from personnel immunized with botulinum pentavalent toxoid (ABCDE) had titers of neutralizing antibodies to type A (5.7 to 51.6 lU/ml), type B (0.75 to 18 lU/ml), and type E (0.61 to 10 IU/ml) botulinum toxins. Titers for one type could not be used to predict titers for another type in individuals receiving the toxoid. Cross-neutralizing antibodies to type F botulinum toxin were not detected (<0.0125 lU/ml).
There are seven types of Clostîidliiiii botîzuliiiiiii. designated A to G. each type producing a pharmacologically similar-but immunologically distinct neurotoxin. ImmunizaLtion with botulinum toxoid has been used for over 40 years to protect laboratory personnel at risk for botulism due to contact with the neurotoxins. The botulinum toxoid currently distributed by the Centers for Disease Control is pentavalent. containing Formalin-inactivated botulinum toxins of type A, B. C. D, and E adsorbed to aluminum phosphate (4) . Toxoids against types F and G are not currently available for human use. However. it has been reported that large quantities of antibody to type E neulotoxin can neutralize small quiantities of type F neurotoxin (2. 3, 12, 15) . This is of particular interest because type F botulinum neurotoxin causes human disease. both foodborne (11, 12) and infant (10) botulism. FUrthermore. there are single strains of C. botuidlinwni that produce type F along with another type of neurotoxin: A + F (7), including a strain isolated from a patient with food-borne botulism (5) . and B + F. isolated from a case of infant botulism (9) . We therefore investigated the possibility that sera from individuals receiving the pentavalent toxoid and having high titers of neutralizing antibodies to type E neurotoxin could also neutralize type F neurotoxin.
As previously described (13) Results are shown in Table 1 . In this group of 25 serum specimens. the A titers ranged from 5.7 to 51.6 lU/ml and the B titers ranged from 0.75 to 18 IU/ml. but the E titers were lower than anticipated, 0.61 to 10 IU/ml ( toxin also neutralized S LD50s of type F toxin (15) . Thus. the type E/type F neutralization ratios previously reported are 1,600/1 for two equine samples (12) and 400/1 for sera from an equine source (2), a rabbit source (15) . and an unknown animal source (3) . In this study for human immune sera. titrations to determine the exact number, if any, of LDS(s of type F toxin that the sera could neutralize were precluded by the lack of sufficient volumes of sera. However. our purpose was to determine whether immunization of personnel with the pentavalent toxoid had elicited levels of cross-neutralizing antibody to type F neurotoxin that could be considered protective.
The correlation between the level of neutralizing antibody in the serum and the ability to withstand an exposure to botulinum toxin is, of course, not known for humans. Values used as '-satisfactory`titers in humans for types A. B. C. D. and E have been extrapolated from animal studies and were established to indicate that an individual had responded to the pentavalent immunogen (6) . These satisfactory levels are twice the lowest titer that can be measured by using the mouse bioassay (1) . Using purified type F monovalent toxoid to immunize guinea pigs. Hatheway demonstrated a relationship between antibody levels and the ability of the animals to survive challenge with 10s LD50s of type F toxin (8) . Ali guinea pigs having antibody concentrations greater than 0.04 U/ml survived challenge, as did 50 to 100Q)r of the animaIs with titers of 0.01 to 0.04 U/ml. However. groups of animalIs with antibody levels that were Lindetectable (<0.01 U/ml) had survival rates of less than 50%7(-, after challenge. Thus 
